tiprankstipranks
Trending News
More News >
Mochida Pharmaceutical Co., Ltd. (DE:MFY)
FRANKFURT:MFY

Mochida Pharmaceutical Co., Ltd. (MFY) Price & Analysis

Compare
0 Followers

MFY Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

2.06%94.47%
Insiders
2.06%
Mutual Funds
― Other Institutional Investors
94.47% Public Companies and
Individual Investors

MFY FAQ

What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Mochida Pharmaceutical Co., Ltd. lowest stock price was €16.60 and its highest was €22.40 in the past 12 months.
    What is Mochida Pharmaceutical Co., Ltd.’s market cap?
    Mochida Pharmaceutical Co., Ltd.’s market cap is €616.16M.
      When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
      Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is Aug 01, 2025 which is in 56 days.
        How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
        Mochida Pharmaceutical Co., Ltd. released its earnings results on May 12, 2025. The company reported €0.014 earnings per share for the quarter, beating the consensus estimate of N/A by €0.014.
          Is Mochida Pharmaceutical Co., Ltd. overvalued?
          According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Mochida Pharmaceutical Co., Ltd. pay dividends?
            Mochida Pharmaceutical Co., Ltd. pays a Annually dividend of €0.245 which represents an annual dividend yield of 2.79%. See more information on Mochida Pharmaceutical Co., Ltd. dividends here
              What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
              Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
              Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.
                What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
                Mochida Pharmaceutical Co., Ltd. reported an EPS of €0.014 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.075%.
                  Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
                  Currently, no hedge funds are holding shares in DE:MFY

                  Company Description

                  Mochida Pharmaceutical Co., Ltd.

                  Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Kaken Pharmaceutical Co
                  Kissei Pharmaceutical Co
                  Towa Pharmaceutical Co
                  KYORIN Pharmaceutical Co.,Ltd.
                  ASKA Pharmaceutical Holdings Co., Ltd.
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis